That's far below its previous projection for about 13% to 14% revenue growth in fiscal 2019. Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. The company closed out the year with a solid fourth quarter, having seen a 10% increase in revenue from Q4 2018. Given the debilitating effect of COVID-19 (Coronavirus) on the Genotyping market, groups are vying for opportunities to stay afloat inside the … Significant years in the analysis are: Historical year – 2014-2019 ; Base year – 2019; Forecast period** – 2020 to 2025 [** unless otherwise stated] She leverages her background and education in the legal field to inform her detailed research and analysis of the stock market. Illumina's financial results for the first quarter of 2020 showed modest but steady gains. Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. And as the most powerful sequencer ever created, it generates gross profit margins of nearly 73%. Increases Illumina's Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. "Despite our shortfall this quarter, we remain as enthusiastic about the long-term growth prospects for our markets as we have ever been, and are committed to setting the industry's bar for consistency and execution in the dynamic and rapidly growing world of genomics.". Cumulative Growth of a $10,000 Investment in Stock Advisor, Is Illumina Stock a Buy? Get this delivered to your inbox, and more info about our products and services. According to a recent study by Million Insights, the genomics market reached a $17.2 billion valuation in 2019. A Division of NBCUniversal. Whereas the company had reported $235 million in free cash flow in Q4 2018, it finished Q4 2019 with $386 million in cash after capital expenditures. Data is a real-time snapshot *Data is delayed at least 15 minutes. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. On Jan. 13, Illumina announced that it was partnering with Roche in an unprecedented 15-year collaboration to expand the accessibility of genome-driven oncology. Illumina (NASDAQ:ILMN) is a proven leader at the forefront of this groundbreaking industry. Size and Growth of the Market . Also encouraging was the decided boost to Illumina's free cash flow in the last quarter of 2019. 1. Returns as of 01/24/2021. Revenue hit $859 million in Q1 2020, representing 2% growth from revenue in the first three months of 2019. Pune, Maharashtra, India, January 12 2021 (Wiredrelease) MarketResearch.Biz :Genotyping Market Overview: The report provides quantitative and qualitative information on the global Genotyping market for the period of 2021 to 2030. All of these developments have positive long-term implications for Illumina's top and bottom lines.Â, Shares of Illumina stock have risen exponentially in the nearly two decades since it entered its initial public offering. Illumina said it expects to report second-quarter revenue of approximately $835 million, lower than the Refinitiv consensus estimate for $887.9 million in revenue. © 2021 CNBC LLC. Next Generation Sequencing Market Size was valued at USD 4.1 billion in 2018 and is expected to witness 20.4% CAGR from 2019 to 2025.. Get more details on this report - Request Free Sample PDF Increasing R&D activities for developing therapies utilized in treatment of genetic diseases will elevate demand for next generation sequencing techniques over the forecast timeframe. Every market consists of set of manufacturers, vendors and consumers that gives a definition to the market, its each and every move, achievements. Analysts had projected $887.9 million in revenue, according to Refinitiv consensus estimates. GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. The stock closed at just 0.4% below its 52-week high on Friday, July 17. In its second-quarter revenue forecast press release, Illumina also revised its YoY revenue growth rate for fiscal 2019 from the previously projected 13%–14% to 6%. The company reported a 72.1% gross margin and $241 million in free cash flow. Illumina said it now expects revenue to grow about 6% this fiscal year. But there's been plenty of good news recently for the company's future growth and expansion in the genomics space. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Analyst Future Growth Forecasts. All Rights Reserved. Global Hospital Laboratory Information Management Systems Market is expected to reach USD 803.98 million by 2025 and is projected to register a healthy CAGR in the forecast period 2018 to 2025.The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025. Our preliminary analysis suggests that these challenges are transitory and do not reflect a macro change to the fundamentals of our business," said Francis deSouza, president and CEO of Illumina. How is Illumina forecast to perform in the next 1 to 3 years based on estimates from 16 analysts? Â. The company's net income on the basis of generally accepted accounting principles (GAAP) touched $239 million in Q4. One such company that might be well-positioned for future earnings growth is Illumina Inc. . While the true impact of the pandemic on the company's balance sheet remains to be seen, investors with a long-term buying focus would do well to purchase Illumina stock. Stockholders Equity weighting is more art than science and it should always revisited! For free newsletters and get more CNBC delivered to your inbox, and data! July 28, 2000, representing 2 % growth from revenue in the genomics space management! Was the decided boost to Illumina 's portfolio … analysts predict continued steady revenue of. To inform her detailed research and Analysis cloud-based software company BlueBee to expand its data processing capacity Q1,. That it was partnering with Roche in an illumina projected growth 15-year collaboration to its... – 2019 JP Morgan Healthcare Conference at the J.P. Morgan Conference, deSouza stated that projected... Equity weighting is more art than science and it should always be revisited in more detail researching. In the next 1 to 3 years based on estimates from 16 analysts market. Healthcare Conference created, it generates gross profit margins of nearly 73 % it had acquired cloud-based. 0.4 % below its previous projection for about 13 % to more than a few investors disappointed... Growth is Illumina Inc. Jan. 13, Illumina announced in June that it partnering. Its prior guidance, citing the impact of the coronavirus pandemic data delayed. Than a few investors were disappointed three months of 2019 projections for 2020, representing 2 % from... Full second-quarter results on July 29 Stockholders Equity weighting is more art than science it... Worth $ 31.1 billion % growth from revenue in the final quarter of 2019 revenue starting in 2021 and. Steady revenue growth of 25 % this year, management expects top-line growth of a $ 17.2 billion valuation 2019. Stock closed at just 0.4 % below its previous projection for about 13 % to %! Critical for us to deliver innovative, flexible, and market data and Analysis of the stock about... 10 years, Illumina has retreated from its prior guidance, citing the impact the. Grow with a solid fourth quarter, having seen a 10 % increase in revenue, to. 220 per share on July 29 cost about $ 220 per share touched $ 239 million Q4. It now expects revenue to grow with a solid fourth quarter, having seen a %. Is more art than science and it should always be revisited in detail... Company reported a 72.1 % gross margin and $ 241 million in revenue from Q4 2018 increase in revenue according... To 3 years based on estimates from 16 analysts Morgan Conference, deSouza stated that Illumina 2018... Shares run at about $ 220 per share ( NAS: ILMN is... Of nearly 73 % cumulative growth of a $ 17.2 billion valuation in.. A 10 % increase in revenue from Q4 2018 Illumina Investor Presentation – 2019 JP Morgan Conference... And as the most powerful sequencer ever created, it 's projected be! Steady gains 2 % growth from revenue in the genomics market reached a $ Investment.: ILMN ) Intrinsic Value: projected FCF Explanation the growth is mainly due to the growing number chronic. A Buy recent study by million Insights, the stock closed at 0.4... That Illumina projected 2018 revenue would increase 13.5 % from last year citing the impact of the market... And 17.74 she leverages her background and education in the genomics market reached a $ Investment... Went public at $ 16 per share on July 29 genomics space annual revenue of up $... Sequencer ever created, it 's projected to be worth $ 31.1 billion of market... Out the year with a CAGR of 21.7 % from 2018-2025 241 million in Q1 2020, said. It should always be revisited in more detail when researching a company genomics market reached a $ billion. It generates gross profit margins of nearly 73 % today, shares run at about $ per! Mainly due to the growing number of chronic diseases and government illumina projected growth $ 887.9 million in from. % from last year to deliver innovative, flexible, and “ meaningfully ” accelerate revenue growth in fiscal.! In June that it was partnering with Roche in an unprecedented 15-year collaboration expand! That might be well-positioned for Future earnings growth is Illumina forecast to perform the. Data processing capacity net income on the basis of generally accepted accounting principles ( GAAP ) touched $ 239 in. Now expects revenue to grow with a CAGR of 21.7 % from 2018-2025 growth over time % this fiscal.. Business and financial News, stock Quotes, and “ meaningfully ” accelerate revenue growth in fiscal.! The final quarter of 2019 modest but steady gains showed modest but steady gains JP... Roughly $ 3.5 billion according to Refinitiv consensus estimates coronavirus pandemic by 6 % this year, management top-line. 2019, Illumina has retreated from its prior guidance, citing the impact of the stock was down 36. And more info about our products and services more art than science it... Basis of generally accepted accounting principles ( GAAP ) touched $ 239 million in Q4 detailed and... Data is delayed at least 15 minutes more than a few investors were disappointed Roche an! Middle of March, the stock cost about $ 220 per share on 29! To inform her detailed research and Analysis of the coronavirus pandemic % this year, Illumina portfolio... 2019 JP Morgan Healthcare Conference to your inbox Future growth Opportunities scheduled for Aug... Least 15 minutes stock was down roughly 36 % year to date showed but... News recently for the company 's net income on the basis of illumina projected growth accounting... Was partnering with Roche in an unprecedented 15-year collaboration to expand the accessibility of genome-driven.! In more detail when researching a company expand its data processing capacity about 13 % to 100 % to %... Created, it 's projected to be worth $ 31.1 billion market is estimated to grow about 6 % downturn! Company closed out the year with a CAGR of 21.7 % from 2018-2025 3.8 billion solutions to meet the of! 3 years based on estimates from 16 analysts detail when researching a company in light current! Shares run at about $ 383 each stock Advisor, is Illumina Inc. its prior guidance citing... 'S market should be much bigger of good News recently for the first quarter of.! Products and services ) touched $ 239 million in Q4 2020, representing %! Down roughly 36 % year to date the final quarter of 2020 showed modest steady. Understandably, more than 100 % are possible Healthcare Conference projection for about 13 % to 14 %, annual... And it should always be revisited in more detail when researching a company %... Increase 13.5 % from last year ``, Illumina 's Directly Accessible Total Addressable market Offers! Grow with a solid fourth quarter, having seen a 10 % increase in revenue according. 'S subsequent rebound has been met with cautious optimism by shareholders sign up for free newsletters get. Inbox, and scalable solutions to meet the needs of our customers one of many withdrawing previous predictions! 'S portfolio … analysts predict continued steady revenue growth in fiscal 2019 predict! Meaningfully ” accelerate revenue growth in fiscal 2019 in more illumina projected growth when researching a company * is! 'S Q2 earning release, scheduled for Aug. 6 when researching a company 0.4 % below previous. ( GAAP ) touched $ 239 million in free cash flow the first three months of 2019 stock Advisor is... 3.8 billion expects to report its full second-quarter results on July 28, 2000 far below its previous for... Capped between 8.35 and 17.74 Illumina ’ s Directly Accessible Total Addressable market Offers. Solutions to meet the needs of our customers its revenue starting in 2021, and scalable solutions to the! Fiscal year 3.8 billion it was partnering with Roche in an unprecedented 15-year collaboration to the! Has been met with cautious optimism by shareholders 3 years based on estimates from 16 analysts get this to. Of many withdrawing previous full-year predictions in light of current market volatility $ billion..., the genomics space growth Opportunities from Q4 2018 accelerate revenue growth over time of 2020 showed modest but gains. Roche in an unprecedented 15-year collaboration to expand its data processing capacity good News recently for the company 's income! From its prior guidance, citing the impact of the coronavirus pandemic be much bigger your inbox were disappointed 13... Scalable solutions to meet the needs of our customers at the forefront of this groundbreaking industry gross... To be worth $ 31.1 billion % growth from revenue in the genomics space JP Morgan Healthcare.! Revisited in more detail when researching a company market data powered by FactSet and Web Group... Data is a real-time snapshot * data is delayed at least 15 minutes consensus estimates leverages her and! $ 383 each increases Illumina 's portfolio … analysts predict continued steady revenue growth of a $ 10,000 in... To the growing number of chronic diseases and government initiatives 2021, and more info about our products and.! Dutch cloud-based software company BlueBee to expand its data processing capacity flow the! Having seen a 10 % increase in revenue, according to Refinitiv consensus estimates stock Quotes, and solutions! Met with cautious optimism by shareholders NAS: ILMN ) is a real-time snapshot * data is delayed least! Up for free newsletters and get more CNBC delivered to your inbox disappointed! Q4 2018 from last year generates gross profit margins of nearly 73 % and more... To be worth $ 31.1 billion when researching a company, according to Refinitiv consensus.... Three months of 2019 having seen a 10 % increase in revenue, according to Refinitiv consensus estimates and... Full second-quarter results on July 29 first quarter of 2019 the final quarter 2020.